**Drug Product Starting Material:**

[ ]  Hematopoietic Progenitor Cell, Apheresis (HPC-A)

[ ]  Hematopoietic Progenitor Cell, Marrow (HPC-M)

[ ]  Hematopoietic Progenitor Cell, Cord Blood (HPC-C)

**Manufacture Information**

Date of Drug Product Manufacture\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

[ ]  Proportion of CD34+ cells \_\_\_\_\_\_\_\_\_

[ ]  Total Colonies Formed: \_\_\_\_\_\_ per \_\_\_\_\_\_\_ cells

Expression of globin chain of interest:

Qualitative Assay: [ ]  Positive [ ]  Negative

[ ]  Quantitative Assay: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Were any additional drug product potency assays performed on drug product?

[ ]  Yes [ ]  No

 If yes, describe and report result\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Type of Modification:

[ ]  Integrating Vector

[ ]  Gene Editing Nuclease

[ ]  Stem Cell Expansion

**POPULATE SECTION A FOR INTEGRATING VECTOR CELL PRODUCT**

**POPULATE SECTION B FOR GENE EDITED CELL PRODUCT**

**Section A**

Type of Integrating Vector: [ ]  Retrovirus [ ]  Lentivirus [ ]  Other\_\_\_\_\_\_\_\_\_\_\_\_\_\_

[ ]  Drug Product VCN\_\_\_\_\_\_

[ ]  Percentage of cells positive for integrating vector \_\_\_\_\_\_\_\_\_

[ ]  Drug Product VCN/cell \_\_\_\_\_\_\_\_

**Section B**

Type of Editing: [ ]  CRISPR-Cas 9 [ ]  ZFN [ ]  TALEN [ ]  Cytosine Base Editing

[ ]  Other\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Mode of nuclease delivery: [ ]  mRNA by EP [ ]  RNP by EP [ ]  AAV

[ ]  Other

gRNA target gene\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Mode of Delivery\_\_\_\_\_\_\_\_\_\_\_

**Donor Template used?** [ ]  Yes [ ]  No

If Yes, mode of delivery: [ ]  ssODN [ ]  AAV [ ]  Other

[ ]  Drug Product:

On-target Indels\_\_\_\_\_\_ Verified off-target indels\_\_\_\_\_\_\_\_\_

Conversion \_\_\_\_\_\_\_%